Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: A population-based study

Psychogeriatrics

Volumn 11, Issue 3, 2011, Pages 150-156

  Lai, Shih Wei ^a,b   Su, Li Ting ^d,e   Lin, Chih Hsueh ^a,b   Tsai, Chon Haw ^a,f   Sung, Fung Chang ^b,e   Hsieh, Dennis Paul Hsientang ^c  

^a Fu Jen Catholic Uiversity   (Taiwan)

^b Department of Public Health ^*  (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d Trauma and Emergency Center   (Taiwan)

^e Management Office for Health Data   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Dementia; Depression; Parkinson's disease; Polypharmacy; Stroke

Indexed keywords

ANTIPARKINSON AGENT;

AGED; ALCOHOLISM; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG USE; FEMALE; GERIATRIC PATIENT; GOUT; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; POLYPHARMACY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; TAIWAN;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG INTERACTIONS; FEMALE; HUMANS; INCIDENCE; MALE; PARKINSON DISEASE, SECONDARY; POLYPHARMACY; RISK FACTORS; TAIWAN;

EID: 80053143386     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2011.00369.x     Document Type: Article

References (27)

1. Morgante L, Nicoletti A, Epifanio A etal. Prevalence of Parkinson's disease and other types of parkinsonism in the Aeolian Archipelago, Sicily. Parkinsonism Relat Disord 2008; 14: 572-575.
2. Wickremaratchi MM, Perera D, O'Loghlen C etal. Prevalence and age of onset of Parkinson's disease in Cardiff: A community based cross sectional study and meta-analysis. J Neurol Neurosurg Psychiatry 2009; 80: 805-807.
3. Wermuth L, Bech S, Petersen MS, Joensen P, Weihe P, Grandjean P. Prevalence and incidence of Parkinson's disease in The Faroe Islands. Acta Neurol Scand 2008; 118: 126-131.
4. Muangpaisan W, Hori H, Brayne C. Systematic review of the prevalence and incidence of Parkinson's disease in Asia. J Epidemiol 2009; 19: 281-293.
5. Chen CC, Chen TF, Hwang YC etal. Different prevalence rates of Parkinson's disease in urban and rural areas: A population-based study in Taiwan. Neuroepidemiology 2009; 33: 350-357.
6. Hancock DB, Martin ER, Mayhew GM etal. Pesticide exposure and risk of Parkinson's disease: A family-based case-control study. BMC Neurol 2008; 8: 6.
7. Priyadarshi A, Khuder SA, Schaub EA, Priyadarshi SS. Environmental risk factors and Parkinson's disease: A meta-analysis. Environ Res 2001; 86: 122-127.
8. Gorell JM, Peterson EL, Rybicki BA, Johnson CC. Multiple risk factors for Parkinson's disease. J Neurol Sci 2004; 217: 169-174.
9. Dick FD, De Palma G, Ahmadi A etal. Environmental risk factors for Parkinson's disease and parkinsonism: The Geoparkinson study. Occup Environ Med 2007; 64: 666-672.
10. Takahashi R, Kawamata J, Takeuchi H. Pathogenesis of sporadic Parkinson's disease: Contribution of genetic and environmental risk factors. Rinsho Shinkeigaku 2009; 49: 885-887 (in Japanese).
11. Tsai CH, Lo SK, See LC etal. Environmental risk factors of young onset Parkinson's disease: A case-control study. Clin Neurol Neurosurg 2002; 104: 328-333.
12. Larson EB, Kukull WA, Buchner D, Reifler BV. Adverse drug reactions associated with global cognitive impairment in elderly persons. Ann Intern Med 1987; 107: 169-173.
13. Gershanik OS. Drug-induced movement disorders. Curr Opin Neurol Neurosurg 1993; 6: 369-376.
14. Detweiler MB, Kalafat N, Kim KY. Drug-induced movement disorders in older adults: An overview for clinical practitioners. Consult Pharm 2007; 22: 149-165.
15. du Souich P. In human therapy, is the drug-drug interaction or the adverse drug reaction the issue? Can J Clin Pharmacol 2001; 8: 153-161.
16. Zopf Y, Rabe C, Neubert A, Hahn EG, Dormann H. Risk factors associated with adverse drug reactions following hospital admission: A prospective analysis of 907 patients in two German university hospitals. Drug Saf 2008; 31: 789-798.
17. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC. Polypharmacy correlates with increased risk for hip fracture in the elderly: A population-based study. Medicine 2010; 89: 295-299.
18. Cheng TM. Taiwan's national health insurance system: High value for the dollar. In: Okma KGH, Crivelli L, eds. Six Countries, Six Reform Models: Their Healthcare Reform, Experience of Israel, The Netherlands, New Zealand, Singapore, Switzerland and Taiwan. Hackensack, NJ: World Scientific, 2009; 171-204.
19. ICD-9-CM Guidelines. [cited 2011 May 25]. Available from URL.
20. Liu CY, Hung YT, Chuang YL etal. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manage 2006; 49: 1-22.
21. Jörgensen T, Johansson S, Kennerfalk A, Wallander MA, Svärdsudd K. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 2001; 35: 1004-1009.
22. Haider SI, Johnell K, Thorslund M, Fastbom J. Analysis of the association between polypharmacy and socioeconomic position among elderly aged ≥77years in Sweden. Clin Ther 2008; 30: 419-427.
23. Chan DC, Hao YT, Wu SC. Characteristics of outpatient prescriptions for frail Taiwanese elders with long-term care needs. Pharmacoepidemiol Drug Saf 2009; 18: 327-334.
24. Visser M, Marinus J, van Hilten JJ, Schipper RG, Stiggelbout AM. Assessing comorbidity in patients with Parkinson's disease. Mov Disord 2004; 19: 824-828.
25. Nuti A, Ceravolo R, Piccinni A etal. Psychiatric comorbidity in a population of Parkinson's disease patients. Eur J Neurol 2004; 11: 315-320.
26. Shulman LM, Taback RL, Bean J, Weiner WJ. Comorbidity of the nonmotor symptoms of Parkinson's disease. Mov Disord 2001; 16: 507-510.
27. Riedel O, Klotsche J, Spottke A etal. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1, 449 outpatients with Parkinson's disease. J Neurol 2010; 257: 1073-1082.